Compare VRTX & ENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VRTX | ENB |
|---|---|---|
| Founded | 1989 | 1949 |
| Country | United States | Canada |
| Employees | N/A | 14800 |
| Industry | EDP Services | Natural Gas Distribution |
| Sector | Technology | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 118.5B |
| IPO Year | 2006 | N/A |
| Metric | VRTX | ENB |
|---|---|---|
| Price | $455.90 | $53.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 27 | 2 |
| Target Price | ★ $526.79 | $65.00 |
| AVG Volume (30 Days) | 1.3M | ★ 5.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 5.09% |
| EPS Growth | ★ 836.54 | N/A |
| EPS | ★ 15.32 | N/A |
| Revenue | ★ $2,488,652,000.00 | N/A |
| Revenue This Year | $10.79 | N/A |
| Revenue Next Year | $10.14 | $3.92 |
| P/E Ratio | $30.10 | ★ $21.67 |
| Revenue Growth | ★ 46.20 | N/A |
| 52 Week Low | $362.50 | $39.73 |
| 52 Week High | $519.68 | $54.42 |
| Indicator | VRTX | ENB |
|---|---|---|
| Relative Strength Index (RSI) | 42.72 | 67.58 |
| Support Level | $455.62 | $45.99 |
| Resistance Level | $465.98 | $54.20 |
| Average True Range (ATR) | 13.17 | 0.86 |
| MACD | -2.82 | 0.06 |
| Stochastic Oscillator | 13.47 | 88.15 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Enbridge owns extensive midstream assets that transport hydrocarbons across the US and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also operates regulated natural gas utilities in the US and Canada, including Canada's largest natural gas distribution company. The firm has a small renewable energy portfolio primarily focused on onshore and offshore wind projects.